In vitro studies by Fagerhol et al. reveal that patients suffering from multiple myeloma have a higher concentration of S100A12/calprotectin complexes than healthy subjects, and S100A12/calprotectin complexes in this study were used as markers of NET release [39]. The gene discussed is S100A12; the disease is plasma cell myeloma.